Among the 33 patients included in this study, the combination of bortezomib and thalidomide was more likely to induce GBS in patients with IgG-type myeloma, whereas the combination of bortezomib and lenalidomide appeared to be more commonly associated with GBS in those patients with IgA-type myeloma. This evidence concerns the gene CD79A and plasma cell myeloma.